Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up.

@article{Wang2019PhaseIS,
  title={Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up.},
  author={Rui Wang and Lillian M Smyth and Neil M Iyengar and Sarat Chandarlapaty and Shanu Modi and Maxine S. Jochelson and Sujata Patil and Larry W. Norton and Clifford A Hudis and Chau T. Dang},
  journal={The oncologist},
  year={2019}
}
BACKGROUND Favorable progression-free survival (PFS) and overall survival (OS) results were previously reported on a phase II trial of patients with human epidermal growth receptor 2 (HER2)-positive metastatic breast cancer (MBC), treated with weekly paclitaxel in combination with trastuzumab and pertuzumab in the first- and second-line setting, with a median follow-up of 33 months. Here, we report updated PFS and OS results with more than 2 years of additional follow-up. MATERIALS AND… CONTINUE READING
17
Twitter Mentions